| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 325 0 |
 SM ISO690:2012CHESOV, Dumitru, CIOBANU, Nelly, LANGE, Christoph G., SCHON, Thomas, HEYCKENDORF, Jan, KRUDU, V.. Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation. In: European Respiratory Journal, 2017, vol. 50, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.01752-2017 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  European Respiratory Journal |
||||||
| Volumul 50 / 2017 / ISSN 0903-1936 /ISSNe 1399-3003 | ||||||
|
||||||
| DOI:https://doi.org/10.1183/13993003.01752-2017 | ||||||
| Pag. 0-0 | ||||||
|
||||||
| Rezumat | ||||||
We are grateful for the response by E. Heldal to our correspondence. Similar to other reports [1] from the World Health Organization (WHO) Euro-Region we found that a high proportion (88%) of Mycobacterium tuberculosis strains from patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) in the Republic of Moldova had a katG 315T mutation, which is strongly suggestive that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR/XDR-TB in this country. |
||||||
| Cuvinte-cheie Antitubercular Agents, Bacterial Proteins, drug resistance, multiple, Bacterial, extensively drug-resistant tuberculosis, Humans, isoniazid, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis, tuberculosis, Multidrug-Resistant |
||||||
|
|
|
|
